General Description

Jaskula-Sztul will explore an antibody-drug conjugate, a novel delivery system for therapy, to increase precision and efficacy while reducing risks. She will be using a natural cytotoxic agent bound to an antibody that specifically targets the surface receptor SSTR2 on pancreatic NETs.

Published Papers

Herring BS, Whitt J, Aweda T, et al. A growth model of neuroendocrine tumor surrogates and the efficacy of a novel somatostatin-receptor-guided antibody-drug-conjugate: Perspectives on clinical response? Surgery. 2020;167, 197-203.